The Lynx Group
Cholangiocarcinoma News

Neoadjuvant Gemcitabine/Cisplatin/Nab-Paclitaxel for Resectable High-Risk iCCA: NEO-GAP

September 2022, Vol 3, No 3

For patients with localized intrahepatic cholangiocarcinoma (iCCA), surgical resection holds curative potential for only 30% to 35% of patients due to its high rate of recurrence. A previous study of gemcitabine/cisplatin/nab-paclitaxel combination chemotherapy (GAP) showed a partial response rate of 45% in locally advanced, unresectable biliary cancer, and 20% of patients who were previously inoperable underwent margin-negative resection.1 The NEO-GAP trial, a multi-institutional, prospective, single-arm, phase 2 study, was conducted to evaluate the GAP regimen in the neoadjuvant setting for patients with resectable but high-risk iCCA.

This feasibility study enrolled patients with resectable high-risk disease (defined as solitary tumor >5 cm, multiple tumors, presence of major vascular invasion, or lymph node involvement). Prior to surgical resection, eligible patients received 4 cycles of the GAP regimen (gemcitabine 800 mg/m2, cisplatin 25 mg/m2, nab-paclitaxel 100 mg/m2 on days 1 and 8 every 21 days). The primary end point was completion of all therapy, including both preoperative chemotherapy and resection. Secondary end points were tolerability, radiologic response, and microscopically margin-negative (R0) resection rate.

A total of 30 patients were enrolled in the study (September 2018-September 2021) and received treatment. The median age of the study population was 61.2 years, and most patients were men (60%). Of the 30 patients, 22 (73%; P = .0106) completed all preoperative chemotherapy and underwent surgical resection.

Grade 3/4 treatment-related adverse events (TRAEs) were reported in 10 (33%) patients; of these, the most common TRAEs were neutropenia and diarrhea. Overall, 50% of the study population required ≥1 dose reductions.

In terms of efficacy, a partial response was achieved by 23% of patients; the disease control rate was 90%, including stable disease in 67% of patients. Of the 22 patients who underwent surgical resection, 2 had minor postoperative complications. Most patients achieved lymph node–negative disease (64%), and 73% had R0 margin status. No treatment-related deaths occurred.

Of the patients who underwent resection following the GAP regimen, the median size of the largest tumor was 5.5 cm; median number of tumors was 3.5. The median length of hospital stay was 4 days.

Based on these results, the researchers concluded that neoadjuvant GAP is feasible and safe prior to curative-intent surgical resection in patients with iCCA and does not adversely affect perioperative outcomes.

Reference

  1. Schroff RT, Javle MM, Xiao L, et al. Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers. JAMA Oncol. 2019;5(6):824-830.

Source: Maithel SK, Javle MM, Mahipal A, et al. NEO-GAP: a phase II single-arm prospective feasibility study of neoadjuvant gemcitabine/cisplatin/nab-paclitaxel for resectable high-risk intrahepatic cholangiocarcinoma. Abstract 4097.

Related Items

GemCis with or without CPI-613 as First-Line Therapy for Patients with Advanced BTCs: The BilT-04 Study
September 2022, Vol 3, No 3
Patients with advanced biliary tract cancers (BTCs) have a poor prognosis despite systemic chemotherapy. Gemcitabine/cisplatin (GemCis) is the standard first-line systemic therapy for BTCs; however, median overall survival was only 11.7 months.
Toripalimab Combined with Gemcitabine and S-1 in the First-Line Treatment of Advanced BTCs
September 2022, Vol 3, No 3
Although gemcitabine plus platinum/fluorouracil combinations are the standard first-line treatment for advanced biliary tract cancers (BTCs), the overall outcomes are suboptimal.
PROs with Durvalumab plus GemCis in Advanced BTCs: The TOPAZ-1 Study
September 2022, Vol 3, No 3
Results of the randomized, double-blind, global, phase 3 TOPAZ-1 trial demonstrated that the first-line chemoimmunotherapy regimen of the PD-L1 inhibitor durvalumab plus gemcitabine/cisplatin (GemCis; median follow-up, 16.8 months) significantly improved overall survival (OS) versus placebo plus GemCis (median follow-up, 15.9 months) in patients with advanced biliary tract cancers (BTCs).1
Regional Subgroup Analysis of Durvalumab plus GemCis in Advanced BTCs: The TOPAZ-1 Study
September 2022, Vol 3, No 3
The randomized, double-blind, global, phase 3 TOPAZ-1 trial demonstrated that the first-line PD-L1 inhibitor durvalumab plus gemcitabine/cisplatin (GemCis; median follow-up, 16.8 months) as first-line treatment significantly improved overall survival (OS) versus placebo plus GemCis (median follow-up, 15.9 months) in patients with advanced biliary tract cancers (BTCs).1
Preservation of Liver Function in Patients with Metastatic iCCA with Extrahepatic Disease
September 2022, Vol 3, No 3
Tumor-related liver failure (TRLF) is the most common cause of death in patients with metastatic intrahepatic cholangiocarcinoma (iCCA), accounting for up to 72% of deaths in patients treated with systemic therapy alone.1
Efficacy and Safety of Futibatinib in iCCA Harboring FGFR2 Fusions/Rearrangements: Updated Results of the FOENIX-CCA2 Trial
September 2022, Vol 3, No 3
Primary analysis of the pivotal, single-arm, phase 2 FOENIX-CCA2 study demonstrated that the FGFR1-4 inhibitor futibatinib as second-line treatment yielded durable objective responses in patients with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusion/rearrangements.
Adjuvant GemCis versus CAP in Patients with Resected Lymph Node–Positive eCCA: The STAMP Study
September 2022, Vol 3, No 3
Adjuvant capecitabine (CAP) is the current standard of care as adjuvant therapy for patients with resected cholangiocarcinoma (CCA); however, patient outcomes are still suboptimal.
CCA Summit Live from ASCO 2022
By Ghassan K. Abou-Alfa, MD, MBA
Videos
Dr Abou-Alfa also provides his perspective on the impact of the data on the management of patients with CCA.
Hot Topics in Cholangiocarcinoma and Biliary Tract Cancers: ASCO Highlights
September/October 2021, Vol 2, No 3
At the CCA Summit during the 2021 Annual Meeting of the American Society of Clinical Oncology (ASCO), Mitesh J. Borad, MD, Associate Professor of Medicine, Mayo Clinic, Phoenix, AZ, reviewed some of the key topics presented at ASCO 2021 related to cholangiocarcinoma (CCA) and other biliary tract cancers. Before turning to the specific presentations, Dr Borad welcomed the May 28, 2021, FDA approval of infigratinib (Truseltiq) for patients with advanced or metastatic CCA and FGFR2 fusions or rearrangements. Infigratinib follows pemigatinib (Pemazyre) as the second targeted therapy now available for this patient population.
CCA Summit Live from ASCO 2021
By Mitesh J. Borad, MD
Videos
On June 8, 2021, Dr Mitesh Borad, Associate Professor of Medicine at the Mayo Clinic in Phoenix, AZ, and a member of the Cholangiocarcinoma Summit Program Steering Committee, presented the top 15 abstracts on the management of cholangiocarcinoma and biliary tract cancer at ASCO 2021.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: